Thyroid hormone use during cardiac transplant organ procurement.

BACKGROUND: Acute hypothyroidism after brain death results in hemodynamic impairments that limit availability of donor hearts. Thyroid hormone infusions can halt that process and lead to increased utilization of donor organs, but prolonged use of thyroid replacement has not been well studied. METHODS: We developed a 15-question survey regarding policies, procedures, and reporting of thyroid hormone use by organ procurement organizations (OPOs). The survey was posted for 5 weeks on the Association of OPOs Portal. RESULTS: We received 29 responses, representing 24 OPOs. Seventy-two percent reported their OPOs use thyroid hormone for all potential donors and 90% have a protocol for thyroid hormone use. There is a large variation in the maximum dose of thyroid hormone used, and many OPOs have no weaning protocol. Most OPOs do not collect data on total thyroid hormone administered during procurement and would favor more detailed report of thyroid hormone use. CONCLUSIONS: Thyroid hormone use can have important implications for organ selection and cardiac function before and after transplantation. Protocols vary widely with respect to why and how to use and wean thyroid hormone. We believe there should be more detailed reporting of thyroid hormone use for future studies to ensure appropriate donor management.

Pursuing expanded criteria donors as candidates for kidney donation after circulatory death.

Of the 119 310 people on the national transplant waiting list, 97 280 people are waiting for kidneys. There simply are not enough organs to meet the demand. Recognizing that 64% of the people waiting for kidney transplants are at least 50 years old, this organ procurement organization embarked on a study to evaluate the potential of increasing the number of viable kidneys available for transplant by pursuing expanded criteria donors as donation after circulatory death (ECD/DCD) candidates. Pursuing ECD/DCD donors resulted in 24 additional donors (50-67 years old), 48 kidneys recovered, 30 kidneys transplanted into 26 recipients (44-74 years old), 7 kidneys placed for research, and 11 kidneys discarded, yielding an overall 62% transplant rate, 15% research rate, and 23% discard rate. The overall discard rate including all donors in all classifications during the study period was 13.1% (122 discards from 928 kidneys) compared with 12.6% (111 discards from 880 kidneys) when the study set was excluded. Although ECD/DCD donors still had the highest discard rates of all the groups, the 0.5% increase in the overall discard rate due to pursuing ECD/DCD kidneys was considered insignificant when compared with the benefit of the 30 additional kidneys transplanted. Including potential ECD/DCD patients in the donor pool increases the number of viable kidneys available for transplant without significantly increasing the overall kidney discard rates.